Ooi Choon Jin, Hilmi Ida, Banerjee Rupa, Chuah Sai Wei, Ng Siew Chien, Wei Shu Chen, Makharia Govind K, Pisespongsa Pises, Chen Min Hu, Ran Zhi Hua, Ye Byong Duk, Park Dong Il, Ling Khoon Lin, Ong David, Ahuja Vineet, Goh Khean Lee, Sollano Jose, Lim Wee Chian, Leung Wai Keung, Ali Raja Affendi Raja, Wu Deng Chyang, Ong Evan, Mustaffa Nazri, Limsrivilai Julajak, Hisamatsu Tadakazu, Yang Suk Kyun, Ouyang Qin, Geary Richard, De Silva Janaka H, Rerknimitr Rungsun, Simadibrata Marcellus, Abdullah Murdani, Leong Rupert Wl
Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore.
Asian Institute of Gastroenterology, New Delhi, India.
Intest Res. 2019 Jul;17(3):285-310. doi: 10.5217/ir.2019.00026. Epub 2019 May 31.
The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn's disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.
亚太炎症性肠病（IBD）工作组在菲律宾宿务成立，由亚太胃肠病学会赞助，目标是改善亚洲的IBD护理。该共识是与亚洲克罗恩病和结肠炎组织合作开展的。随着生物制剂和生物类似药的日益普及，有必要对现有文献进行综述，并就是否以及如何在亚洲将生物制剂和生物类似药与溃疡性结肠炎（UC）和克罗恩病（CD）的传统治疗相结合达成共识。这些声明还讨论了药物遗传学如何影响UC和CD的治疗，并为反应监测和恢复反应丧失的策略提供指导。最后，综述包括关于如何在可能同时感染乙型肝炎和结核病（这两种疾病在亚洲都很常见）的情况下管理治疗的声明。这些声明由IBD工作组的成员采用改良的德尔菲法编制并投票通过。这些声明并非旨在涵盖所有方面，随着新数据不断出现，未来可能会进行修订。
